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Post Analysis From Two Randomized Trials of
irolimus-Eluting Stents Versus Paclitaxel-Eluting
tents in High-Risk Patients With Coronary Artery Disease
hpend Elezi, MD,* Alban Dibra, MD,* Ulrike Folkerts, MD,* Julinda Mehilli, MD,* Sylvia Heigl,†
lbert Schömig, MD,† Adnan Kastrati, MD*
unich, Germany
OBJECTIVES This study sought to analyze the cost of percutaneous coronary interventions with use of
sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) in patients at high risk of
restenosis.
BACKGROUND Recent studies have shown different clinical efficacy with these drug-eluting stents. Whether
this difference extends on cost estimates between the 2 stents is not known.
METHODS We included 450 patients with diabetes mellitus and in-stent restenosis from 2 randomized
studies comparing SES with PES. Assigned costs for the economic evaluation were the initial
hospitalization and all subsequent cardiac-related inpatient/outpatient health resources
during 9 to 12 months of clinical follow-up. The economic evaluation was performed from
the health insurance system’s perspective.
RESULTS There were no differences between the 2 study groups regarding mortality (p  0.78) and
myocardial infarction rates (p  0.76). Target lesion revascularization was performed in 16
patients (7.1%) in the SES group and in 34 patients (15.1%) in the PES group (p  0.01).
Initial hospital costs were not significantly different between the 2 stents (p  0.53). The
follow-up costs were, however, different: 2,684  2,072€ per patient treated with SES and
4,527 6,466€ per patient treated with PES (p 0.001). Total costs also differed at the end
of the follow-up: 8,924  3,077€ per patient treated with SES and 10,903  7,205€ per
patient treated with PES (p  0.001).
CONCLUSIONS In patients at high risk of restenosis, use of SES is associated with lower costs compared with
PES. The cost savings are mainly due to the reduced need of repeat revascularization
procedures with SES. (J Am Coll Cardiol 2006;48:262–7) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.080of Cardiology Foundation
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trug-eluting stents (DES) are the most recent major tech-
ological advance in percutaneous coronary interventions
PCIs) (1). They work by releasing controlled amounts of
ntiproliferative agents at the local level, leading to the sup-
ression of neointimal proliferation, which is the chief cause of
estenosis after stent implantation (2,3). Although several DES
See page 268
ave been developed, only 2 of them, the sirolimus-eluting
tents (SES) and the paclitaxel-eluting stents (PES), are
urrently approved for use (2,4,5). In the last few years,
umerous randomized trials have studied the clinical impact of
ES and PES in various subsets of patients with coronary
rtery disease. Accumulated evidence demonstrates that, com-
ared to bare-metal stents (BMS), DES are highly effective in
educing angiographic restenosis and the need for repeat
evascularization procedures, and their benefit also extends to
atients with high-risk angiographic and clinical characteristics
6–11).
From the *Deutsches Herzzentrum and the †1. Medizinische Klinik rechts der Isar,
echnische Universität; Munich, Germany. Dr. Kastrati reports having received
ecture fees from Bristol-Myers, Cordis, Glaxo, Lilly, Medtronic, and Sanofi-Aventis.e
Manuscript received November 15, 2005; revised manuscript received January 26,
006, accepted January 29, 2006.The better clinical efficacy of DES comes, however, at a
ubstantially higher price (12). As the economic burden of
ew technologies plays an important role in the decision-
aking process of their acceptance in clinical practice,
pecial attention has been paid to the economic impact of
ES. Recently, the results of two studies suggested that, in
he context of randomized studies involving patients treated
or single de novo lesions, use of SES is cost-effective
13,14). Similar results have also been reported from an-
ther study, which estimated the cost-effectiveness of the
ES in an unselected patient population (15). Although
ifferences between studies may exist regarding the analyzed
atient populations, methods used for the assessment of
ost-effectiveness, and magnitude of benefit with DES, it is
ommonly accepted that use of DES will be cost-effective
or most patients undergoing PCIs, in particular for those
onsidered to have a high risk of restenosis (12).
Recently, several studies have assessed the relative efficacy
f the SES and PES in patients with various risk profiles
16–19). The results of these studies as well as of their
eta-analysis show that SES are associated with better
utcomes than PES (16–20). It is not known, however,
hether treatment with SES could also be economically
ore attractive than PES. This issue is of particular impor-
ance considering the high cost of these devices and their
xpanding utilization during PCIs (12,21).
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July 18, 2006:262–7 Comparative Cost Analysis of Drug-Eluting StentsThe goal of this study was to evaluate the costs of PCIs
ith implantation of SES and PES in patients who are at
igh risk of restenosis, such as those with diabetes and
n-stent restenosis, in relation to the clinical effectiveness of
he 2 stent types.
ETHODS
atients. This study evaluated data collected from 450
atients who participated in the DES arms of the ISAR-
ESIRE (Intracoronary Stenting and Angiographic Re-
ults: Drug-Eluting Stents for In-Stent Restenosis) and
SAR-DIABETES (Intracoronary Stenting and Angio-
raphic Results: Do Diabetic Patients Derive Similar Ben-
fit from Paclitaxel-Eluting and Sirolimus-Eluting Stents?)
andomized studies. Details of patients’ recruitment and
esign of the studies have been described elsewhere (16,18).
ll patients were pre-treated with a 600-mg loading dose of
lopidogrel at least 2 h before the intervention. Both trials
ad follow-up angiography scheduled at 6 to 8 months after
andomization as part of their protocol. Patients were
ollowed up clinically for 9 to 12 months. Specifically, the
SAR-DESIRE trial was a randomized, open-label con-
rolled study conducted among 300 patients with angio-
raphically significant in-stent restenosis. The primary end
oint of the study was recurrent angiographic restenosis at
ollow-up angiography. All patients were randomly assigned
o 1 of the 3 treatment groups: sirolimus stent, paclitaxel
tent, or balloon angioplasty (100 patients in each group).
dverse events monitored were death, myocardial infarc-
ion, and target lesion revascularization. Reintervention was
erformed according to the decision of investigators based
n symptoms and/or signs of ischemia. The ISAR-
IABETES study enrolled 250 diabetic patients with
oronary artery disease. Of these, 125 were assigned to
reatment with PES and 125 to treatment with SES. The
rimary end point was in-segment late lumen loss. Adverse
vents monitored were death, myocardial infarction, and
Abbreviations and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ISAR-DESIRE  Intracoronary Stenting and
Angiographic Results: Drug-
Eluting Stents for In-Stent
Restenosis
ISAR-DIABETES  Intracoronary Stenting and
Angiographic Results: Do
Diabetic Patients Derive Similar
Benefit from Paclitaxel-Eluting
and Sirolimus-Eluting Stents?
MACE  major adverse cardiac event
PCI  percutaneous coronary
intervention
PES  paclitaxel-eluting stent(s)
SES  sirolimus-eluting stent(s)arget lesion revascularization. tExclusion criteria for both studies included acute ST-
egment elevation myocardial infarction; a target lesion
ocated in left main trunk or bypass grafts; and contraindi-
ations to aspirin, heparin, and clopidogrel. For the ISAR-
IABETES trial, in-stent restenosis was also an exclusion
riterion.
Clinical outcomes of interest for the present study were
eath, myocardial infarction, and target lesion revascular-
zation. The diagnosis of myocardial infarction during
ollow-up was made in the presence of new Q waves in the
lectrocardiogram and/or an elevation of creatine kinase or
ts MB isoenzyme to at least 3 times the upper limit of
ormal. Target lesion revascularization was defined as any
epeat PCI or aortocoronary bypass surgery involving the
arget lesion. The angiographic outcome of interest was
inary angiographic restenosis, which was defined as a
iameter stenosis of at least 50% in the segment including
he stented segment as well as its 5-mm proximal and distal
argins at follow-up angiography.
osts. We investigated the costs that health insurance com-
anies have to reimburse hospitals and not the actual cost
ncurred by hospitals. According to the German health care
ystem, during the time period in which the ISAR-DESIRE
nd ISAR-DIABETES studies were carried out, hospitals
ere reimbursed by a 2-tier system of charges. The first
omponent consisted of a hospital-specific basic per diem
overing non-medical costs and a department-specific per
iem covering medical costs including nursing, pharmaceu-
icals, and procedures. The second component consisted of
ase fees (covering the costs for a patient’s entire hospital
tay) and procedure fees (paid on top of slightly reduced per
iems). Case fees were based on a combination of a certain
iagnosis (4-digit International Classification of Diseases,
inth Revision) and a specific intervention. These fees were
et through an ordinance by the Federal Ministry of Health,
hile the monetary conversion factor was negotiated at land
evel each year separately between sickness (health insur-
nce) funds and hospitals. For the purpose of this analysis,
unning costs were collected from hospital financial depart-
ents for each patient enrolled in the study. Running costs
ncluded personnel costs, as hospital physicians are salaried
mployees of the hospitals. Running costs were calculated
y summing case fees, procedure fees, and per diem charges,
s appropriate for the specific year.
Costs incurred from the use of medical resources before
nclusion of patients in the 2 randomized studies were not
ncluded in the present analysis. Assigned costs for the
conomic evaluation were the initial hospitalization and all
ubsequent cardiac-related inpatient or outpatient health
esources usages during clinical follow-up, excluding med-
cations used outside a health care facility. The costs of the
rotocol-specified angiogram admission were included in
he follow-up costs, but as they were incurred by both
roups, these costs had no material relevance to our analysis.
ndirect costs such as productivity loss were not included in
he analysis; thus, only direct medical costs were analyzed.
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Comparative Cost Analysis of Drug-Eluting Stents July 18, 2006:262–7he economic evaluation was performed from the health
nsurance system’s perspective. Total costs per patient were
easured as the sum of initial hospital costs and follow-up
ospital or outpatient visit costs (9 months for the ISAR-
IABETES study and 1 year for the ISAR-DESIRE
tudy). All costs are expressed in euros. The protocol of
his study was designed to calculate incremental cost-
ffectiveness ratio (additional cost per additional event-free
urvivor) in case higher efficacy was associated with higher
osts.
tatistical analysis. The data are presented as means 
D; or counts or percentages. Continuous data were com-
ared with the Student t test. Categorical data were com-
ared with the chi-square test or the Fisher exact test when
xpected cell values were 5. A p  0.05 was considered to
ndicate statistical significance.
ESULTS
total of 450 patients were included in this study; one-half
225 patients) received SES and the other one-half PES.
able 1 shows the baseline demographic, clinical, and
ngiographic characteristics of the study population. There
ere no significant differences on demographic characteris-
ics between the two groups. Also, vessel size and lesion
ength were similar among patients assigned to the SES and
ES groups. There were also no differences with respect to
he number of stents used and length of stented segments.
nly 1 diabetic patient in the PES group suffered early stent
hrombosis. There were no significant differences in the
tandard medications provided to the patients in the respec-
ive DES groups.
fficacy. Clinical outcomes are presented in Table 2. Clin-
cal follow-up was completed in all patients. Mean clinical
Table 1. Baseline Characteristics of the Patien
Characteristic
Age, yrs
Female gender (%)
Diabetes mellitus
Current smoker
Arterial hypertension
Hypercholesterolemia
Unstable angina
Prior myocardial infarction
Prior aortocoronary bypass surgery
Left ventricular ejection fraction, %
Target vessel
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Length of stented segment, mm
No. of stents
Vessel size, mm
Lesion length, mm
Diameter stenosis before procedure, %
Values are means  SD or n (%).
PES  paclitaxel-eluting stent; SES  sirolimus-elutingollow-up interval was 311 days for the SES group and 308 iays for the PES group (p  0.61). Six patients (2.7%) in
he SES group and 7 patients (3.1%) in the PES group died
ithin this period of time (p 0.78). Myocardial infarction
ccurred in 6 patients (2.7%) in the SES group and in 5
atients (2.2%) in the PES group (p  0.76). Target lesion
evascularization was performed in 16 patients (7.1%) in the
ES group and in 34 patients (15.1%) in the PES group
p  0.01). Two patients in the PES group, but none in the
ES group, required coronary bypass surgery. Of the 50
atients who underwent target lesion revascularization, 34
atients (10 in the SES group and 24 in the PES group)
equired repeat intervention before scheduled follow-up
ngiography. There were 27 patients (12%) with major
dverse cardiac events (MACE) in the SES group and 43
atients (19%) with MACE in the PES group (p  0.04).
Follow-up angiography was performed in 193 patients
86%) in the SES group and in 195 patients (86%) in the
ES group. Binary angiographic restenosis was found in 20
atients (10.4%) in the SES group and in 37 patients (19%)
n the PES group (p  0.02). There was no significant
ifference between the 2 groups regarding the total length of
n-hospital stay for all hospitalizations needed during the
d the Lesions
SES PES
 225) (n  225) p Value
 10.5 66.9  10.3 0.26
4 (24) 57 (25) 0.57
6 (69) 152 (68) 0.68
9 (13) 25 (11) 0.56
1 (54) 138 (61) 0.11
1 (58) 131 (58) 1
5 (33) 64 (28) 0.26
4 (37) 104 (46) 0.06
9 (13) 28 (12) 0.89
 12.6 52.9  12.4 0.42
0.79
4 (46) 106 (47)
3 (28) 67 (30)
8 (26) 52 (23)
 9.6 22.4  9.4 0.24
 0.36 1.10  0.38 0.78
 0.49 2.70  0.52 0.33
 7.7 13.3  8.3 0.46
 14.2 60.3  13.0 0.15
able 2. Clinical Outcome at Follow-Up
SES PES
Characteristic (n  225) (n  225) p Value
eath 6 (2.7) 7 (3.1) 0.78
yocardial infarction 6 (2.7) 5 (2.2) 0.76
eintervention 16 (7.1) 34 (15.1) 0.01
Re-PTCA 16 (7.1) 32 (14.2) 0.02
Bypass 0 (0.0) 2 (0.9) 0.50*
ajor adverse cardiac events 27 (12) 43 (19) 0.04
Fisher exact test. Values are n (%).ts an
(n
65.8
5
15
2
12
13
7
8
2
51.9
10
6
5
23.5
1.10
2.66
13.9
62.1PCTA  percutaneous transluminal coronary angioplasty; other abbreviations as
n Table 1.
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July 18, 2006:262–7 Comparative Cost Analysis of Drug-Eluting Stentsollow-up period: 4  3 days in the SES group and 4  2
ays in the PES group (p  0.92).
osts. Table 3 presents a cost analysis between SES and
ES. Initial hospital costs with SES were not significantly
ifferent compared to PES. The mean follow-up costs were,
owever, significantly different, amounting to 2,684 
,072€ per patient treated with SES and 4,527  6,466€
er patient treated with PES (p  0.001) (Fig. 1). Also,
ean total costs were significantly different at the end of the
ollow-up period: 8,924  3,077€ per patient treated with
ES and 10,903  7,205€ (p  0.001) per patient treated
ith PES.
Table 3 also presents subgroup cost analyses divided
ccording to the presence or absence of diabetes mellitus. In
he first subgroup analysis with only diabetic patients, there
able 3. Initial Hospital, Follow-Up, and Total Costs (in Euros)
SES PES p Value
hole-study cohort (n) 225 225
Initial hospital costs 6,240  2,202 6,377  2,374 0.53
Follow-up costs 2,684  2,072 4,527  6,466 0.001
Total costs 8,924  3,077 10,903  7,205 0.001
iabetic patients (n) 156 152
Initial hospital costs 6,498  2,410 6,771  2,597 0.34
Follow-up costs 2,668  1,988 4,589  7,051 0.001
Total costs 9,166  3,200 11,360  7,941 0.002
on-diabetic patients (n) 69 73
Initial hospital costs 5,658  1,496 5,557  1,543 0.69
Follow-up costs 2,720  2,265 4,397  5,077 0.01
Total costs 8,378  2,724 9,954  5,282 0.03
e novo lesions (n) 125 125
Initial hospital costs 6,726  2,484 6,833  2,537 0.74
Follow-up costs 2,734  2,100 4,708  7,385 0.004
Total costs 9,461  3,319 11,542  8,306 0.01
estenotic lesions (n) 100 100
Initial hospital costs 5,632  1,602 5,805  2,025 0.50
Follow-up costs 2,621  2,046 4,300  5,118 0.003
Total costs 8,254  2,610 10,106  5,467 0.003
alues are means  SD in €.
Abbreviations as in Table 1.igure 1. Initial hospital costs and follow-up costs for the patients who underwen
or the difference between the 2 drug-eluting stents with respect to follow-up cas a significant difference in the average total costs be-
ween the SES and the PES (9,166  3,200€ vs. 11,360 
,941€; p  0.002). Similarly, in the non-diabetic subgroup
f the study population, there was a significant difference in
he total costs calculated for the SES as compared with PES
8,378  2,724€ vs. 9,954  5,282€; p  0.03). It is worth
bserving that diabetic patients had higher costs than
on-diabetic patients during the initial hospitalization and
uring follow-up for both the SES and PES groups.
Follow-up costs in the subset of patients without target
esion revascularization were similar between the SES and
ES groups (2,450 1,928€ vs. 2,905 4,014€; p 0.14),
mplying that the difference in total costs between the 2
roups of patients was mainly due to the higher rate of
arget lesion revascularization incurred during follow-up
mong patients treated with PES.
The analysis of the efficacy and costs in this study showed
hat use of SES is a cost-saving (dominant) treatment
trategy, being associated with a higher effectiveness and
educed costs. Therefore, there was no need for analyzing
he cost-effectiveness relationship between the two study
roups.
ISCUSSION
his is the first study to comparatively evaluate the costs of
he currently approved DES, the SES and the PES, in
elation to their clinical effectiveness when used in patients
ith coronary artery disease. Both groups of patients treated
ith the respective DES had an overall low rate of MACE,
lthough a significantly smaller number of patients in the
ES group experienced MACE. There were no differences
etween patients in the 2 stent groups with respect to
ortality and myocardial infarction rates during the
ollow-up period. On the other hand, patients assigned to
he SES group had significantly lower rates of angiographic
nd clinical restenosis compared with patients assigned tot implantation of sirolimus-eluting and paclitaxel-eluting stents. p 0.001
osts.
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Comparative Cost Analysis of Drug-Eluting Stents July 18, 2006:262–7he PES group. Hence, the difference in clinical effective-
ess between the 2 DES in this study is attributed to the
educed need of repeat revascularization procedures with
ES. We found that although the initial hospital costs were
imilar for both stent groups, there was a significant differ-
nce in follow-up and in total costs that favored the SES
roup. Higher costs associated with the use of PES almost
ntirely reflect the difference in the efficacy in the reduction
f repeat revascularization procedures between the 2 DES.
Although use of DES is associated with a marked clinical
enefit among patients with coronary artery disease, con-
erns remain with respect to their high costs. Therefore, for
DES platform to achieve acceptability and widespread use,
n optimal balance between cost and effectiveness should be
emonstrated in addition to clinical efficacy (12). In this
ontext, head-to-head comparisons of different DES would
llow a full appreciation, from different perspectives (includ-
ng the societal perspective), of the economic impact of
ntroducing or expanding the use of different types of DES.
ur study shows that because of the difference in clinical
ffectiveness, use of DES that perform better will be a
ost-saving strategy, provided initial hospital costs are similar.
Calculated costs for initial hospitalization, follow-up, and
otal costs for the SES in our study were similar to those
eported in previously published analyses (13,14) that com-
ared costs associated with use of DES and BMS. These
tudies found reasonable balance between costs and effects
or SES as compared with BMS for both simple and
omplex coronary lesions. Basically, both previous studies
nalyzed all the resources used during initial interventions
nd at follow-up, including hospitalization days, different
ees, and use of medical and other materials, and unit costs
ere estimated for each resource used. Our approach was to
xamine the costs from insurer perspectives, which are
nterested in the overall costs for a disease and intervention
ithout focusing on the variations in inter-institutional use
f resources and on the unit prices. It is also interesting to
ote that the total costs in our study compare favorably with
hose reported from historical studies on treatment of
omplex lesions, including restenotic lesions treated with
alloon angioplasty or intracoronary brachytherapy (22–25);
owever, it is difficult to compare costs in different countries
nd in different time periods because of various factors,
ncluding different unit prices and inflation rates. Though
he precise euro amounts may not be readily translated, the
irectionality of our findings probably is translatable.
Our analysis was performed from the health insurance
ystem’s perspective as an approximation for the societal
erspective. It is important to emphasize the perspective
rom which the economic evaluation is performed (26). The
ayer perspective is the only entity that reaps the overall
enefits of this sort of cost-effectiveness. It is also worthy to
ote that other perspectives, such as the provider (physicians
r hospitals) would not reap the benefit of this cost-
ffectiveness. Indeed, for the hospitals it is a double jeopardy mf losing future revenues and bearing the higher costs of
ES versus BMS.
Indirect costs were not measured, and thus the total costs
stimated in this study may not provide a complete picture
f the cost estimates from the societal perspective. The
nginal pain and the accompanying anxiety extended be-
ond pain period, disability, productivity loss, and possible
ncrease of hospitalization appear to justify the increasing
se of revascularization as an end point in cost-effectiveness
alculations in recent studies, especially from the payer,
atient, and societal perspectives (13,23,27). Therefore, the
igher rate of revascularization may well reflect increased
ndirect costs and decreased quality of life. A recent study
ound that patients undergoing PCIs assign an important
alue to the avoidance of restenosis (28). Thus, inclusion of
hese measurements probably would have increased the
ifference in costs between our study groups.
Our analysis is based on the ISAR-DESIRE and ISAR-
IABETES studies, which included patients with in-stent
estenosis and diabetic patients. This is a high-risk popula-
ion, and the results of this study do not necessarily apply to
ther patient subsets. Therefore, further studies must be
onducted to assess not only efficacy but also costs of
ntervention of these 2 platforms of DES.
Mandatory, protocol-driven angiographic follow-up of
he study population may have increased the frequency of
epeat revascularization procedures and, consequently, total
osts. However, the possible inflated cost for this increase in
einterventions is likely to be balanced between both groups
s a consequence of the randomization process and the
imilar rate of angiographic follow-up. Therefore, the bias
oward any of the study cohort groups should be minimal.
he fact that the majority of patients who underwent target
esion revascularization required repeat intervention before
he scheduled follow-up angiography further reduces the
ossible bias related to protocol-mandated angiographic
ollow-up.
Quality of life was not assessed in this study. There were
o quality-measuring instruments designed in the protocols
f the randomized trials, which provided the patients for
his analysis. Quality-adjusted year of life gained as a
tandard cost-effectiveness measure would have allowed for
omparison across different diseases as opposed to the
isease-specific measure, such as cost per repeat revascular-
zation procedure avoided.
In conclusion, the results of this study show that use of
ES is economically more attractive than PES in patients
ith coronary artery disease presenting with high clinical
nd angiographic risk profiles. Implantation of the SES is a
ost-saving strategy, mainly because of the significant re-
uction in clinical restenosis with this DES.
eprint requests and correspondence: Dr. Adnan Kastrati,
eutsches Herzzentrum Lazarettstr. 36, 80636 Munich, Ger-
any. E-mail: kastrati@dhm.mhn.de.
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